Study of MDX-010 in Stage IV Breast Cancer
Public ClinicalTrials.gov record NCT00083278. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase II Study of MDX-010 in Patients With Stage IV Adenocarcinoma of the Breast
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This Phase II study is designed to treat patients who have been diagnosed with Stage IV Breast Cancer, which has progressed despite treatment with primary therapies, including hormonal therapy, chemotherapy, and antibody therapy. Thirty-three patients will be treated with the monoclonal antibody MDX-010. The initial antitumor activity profile of MDX-010 will be determined, as well as identification of the induction of any antitumor immunity following the MDX-010 treatment.
Study identification
- NCT ID
- NCT00083278
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 33 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 2003 (Type not available)
- Primary completion
- Not listed
- Completion
- Feb 2006 (Actual)
- Last update posted
- Apr 27, 2012
2003 – 2006
United States locations
- U.S. sites
- 14
- U.S. states
- 6
- U.S. cities
- 10
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Sharp Clinical Oncology Research | San Diego | California | 92123 | — |
| Wishard Health Services | Indianapolis | Indiana | 46202-2859 | — |
| Section of Hematology/Oncology, Indiana Cancer Pavilion | Indianapolis | Indiana | 46202-5289 | — |
| Indiana University, Clarian Health Partners | Indianapolis | Indiana | 46202 | — |
| Medical Arts Building | Jeffersonville | Indiana | 47130 | — |
| Kansas City Oncology and Hematology Group | Kansas City | Kansas | 66112 | — |
| Kansas City Oncology and Hematology Group | Overland Park | Kansas | 66210 | — |
| LaGrange | La Grange | Kentucky | 40031 | — |
| Norton Healthcare Inc, Loiusville Oncology Clinical Research Program | Louisville | Kentucky | 40202 | — |
| Suburban Medical Plaza II | Louisville | Kentucky | 40207 | — |
| Audubon Oncology/Hematology | Louisville | Kentucky | 40217 | — |
| Kansas City Oncology and Hematology Group | Kansas City | Missouri | 64131 | — |
| Kansas City Oncology and Hematology Group | Lee's Summit | Missouri | 64064 | — |
| Arlington Cancer Center | Arlington | Texas | 76012 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00083278, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 27, 2012 · Synced Oct 4, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00083278 live on ClinicalTrials.gov.